On November 19, 2023, in the immunotherapy branch of the Fourth Precision Medicine Conference in 2023 held in Guangzhou Yuexiu International Conference Center, our chief scientist Professor Wang Jianxun gave a speech on the theme of "The Establishment of standardized industrial Production System GMP for retroviral Vectors". And on behalf of Shenzhen Cell Valley and Tesai Immunology (Guangzhou) Technology Co., Ltd. held a strategic cooperation signing ceremony. The two parties will carry out the development of TCR-T cell therapy pipeline based on retroviral vector, and carry out comprehensive cooperation in the direction of IIT clinical research and IND application of new drugs, deepening the research and development of TCR-T cell therapy, through the core technology of Shenzhen Cell Valley - efficient and stable retroviral vector, Promote TCR-T research and clinical application to a new height, and make positive contributions to truly benefiting the majority of cancer patients.